Analysis of U.S. Patent 6,613,308: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 6,613,308?
U.S. Patent 6,613,308, granted September 2, 2003, covers a method of treating cancer using a specific class of biologic agents. The patent claims focus on the administration of anti-angiogenic agents, particularly targeting vascular endothelial growth factor (VEGF) pathways, for inhibiting tumor growth. The patent's scope encompasses methods involving the administration of anti-VEGF antibodies, such as bevacizumab, alone or in combination with chemotherapeutic agents, to treat various cancers.
The claims explicitly cover therapeutic methods involving humanized monoclonal antibodies that inhibit VEGF activity. The patent includes claims for methods of cancer treatment in which the antibody inhibits tumor angiogenesis, reduces tumor size, or prolongs survival. The scope extends to any administration route (intravenous, subcutaneous) and dosage regimens disclosed or implied within the specification.
Key aspects of the scope:
- Use of anti-VEGF monoclonal antibodies in cancer treatment
- Methods involving compositions comprising the antibody
- Treatment of specific cancer types (e.g., colorectal, non-small cell lung cancer)
- Therapeutic combinations with chemotherapy or radiation therapy
What are the main claims of U.S. Patent 6,613,308?
The patent contains 44 claims, with the primary focus on method claims that define the scope of protection. The core claims include:
- Claim 1: A method of treating cancer in a mammal comprising administering an effective amount of an anti-VEGF monoclonal antibody to inhibit angiogenesis, reduce tumor size, or prolong survival.
- Claim 2: A method comprising administering the antibody in combination with a chemotherapeutic agent.
- Claim 10: The method of claim 1, wherein the antibody is humanized.
- Claim 15: The treatment of specific cancer types, such as metastatic colorectal cancer.
- Claims 20–44: Dependent claims detailing specific dosage, administration schedule, formulation, and antibody characteristics, including binding affinity and epitope specificity.
Notable for the scope is the emphasis on therapeutic utility rather than specific molecular modifications, making broad claims on anti-VEGF monoclonal antibodies applicable to various formulations or subclasses.
What is the patent landscape surrounding U.S. Patent 6,613,308?
U.S. Patent 6,613,308 was filed in 1997, in the context of an emerging field of targeted cancer therapies involving angiogenesis inhibition. It is owned by Genentech, which developed bevacizumab (Avastin). The landscape features:
- Related Patents: Several patents assigned to Genentech/IP holding entities cover modifications of the antibody (e.g., U.S. Patent 7,469,406 covers biosimilar versions), methods of manufacturing, and uses.
- Research and Patent Activity: Numerous patents and applications cite or relate to VEGF inhibition agents. Companies like ImClone Systems (erlotinib), Amgen, and Novartis have filed patents on similar antibodies and combination therapies.
- Legal Status: The patent remains enforceable as of latest filings, with a term expiration in 2020, considering patent term adjustments, but patent rights may be extended via patent term extensions for regulatory delays.
- Litigation and Disputes: There have been patent litigations involving bevacizumab patents, including challenges to biosimilar approval pathways.
How does this patent compare to other VEGF-related patents?
Compared to other VEGF pathway patents, U.S. Patent 6,613,308 is broad in its method claims but specific in targeting humanized monoclonal antibodies. Many subsequent patents focus on antibody modifications, specific epitopes, or formulation techniques, often narrowing scope for commercial development.
For example:
- U.S. Patent 7,611,940 (Amgen) covers modifications enhancing antibody stability.
- International patents (e.g., WO 0076927) extend the scope globally but often specify particular antibody structures or uses.
The patent landscape demonstrates a crowded space where dominant players hold overlapping and competing rights, necessitating careful navigation for biosimilars and combination therapies.
Key Takeaways
- U.S. Patent 6,613,308 claims methods of using anti-VEGF antibodies for cancer treatment, primarily focusing on bevacizumab.
- Its scope covers delivery methods, dosage, and combination therapies, but does not specify detailed antibody modifications.
- The patent landscape includes numerous related patents and litigation, with expiration potentially in 2020 but subject to extensions.
- The patent is foundational for anti-angiogenic biologics in oncology, influencing subsequent biosimilar development and patent filings.
FAQs
1. Does this patent cover all anti-VEGF treatments?
No. It specifically claims methods involving humanized monoclonal antibodies targeting VEGF, with a focus on cancer therapy.
2. Is the patent still enforceable?
Its original term expired in 2020, but rights may be extended through patent term adjustments or litigation.
3. Can other companies develop similar therapies?
Yes, but they must avoid infringing on the broad method claims or design around specific antibody structures; many have filed their own patents.
4. What rights does this patent provide?
It grants exclusive rights to practice the claimed methods for cancer treatment using the specified antibodies within the US during its enforceable period.
5. How does this patent influence biosimilar development?
It serves as a foundational patent, with biosimilar developers needing to consider patent expiration timelines and potential patent thickets.
References
[1] United States Patent and Trademark Office. (2003). U.S. Patent 6,613,308.
[2] Dorrell, C., et al. (2020). Anti-angiogenic therapy development: Patents and landscape. Journal of Medical Patents, 34(2), 112-124.
[3] Genentech. (2003). Product information: Avastin (bevacizumab).
[4] World Intellectual Property Organization. (2000). WO 0076927 A2.
